Cited by 272Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.

Therapeutic cancer vaccines: are we there yet?

Open access

Klebanoff, Christopher A., Acquavella, Nicolas, Yu, Zhiya, Restifo, Nicholas P.·2011·Immunological Reviews

DOI 10.1111/j.1600-065x.2010.00979.xPMC PMC3075547

Open this paper in CoChat — free account

Abstract

Summary: Enthusiasm for therapeutic cancer vaccines has been rejuvenated with the recent completion of several large, randomized phase III clinical trials that in some cases have reported an improvement in progression free or overall survival. However, an honest appraisal of their efficacy reveals modest clinical benefit and a frequent requirement for patients with relatively indolent cancers and minimal or no measurable disease. Experience with adoptive cell transfer‐based immunotherapies unequivocally establishes that T cells can mediate durable complete responses, even in the setting of advanced metastatic disease. Further, these findings reveal that the successful vaccines of the future must confront: (i) a corrupted tumor microenvironment containing regulatory T cells and aberrantly matured myeloid cells, (ii) a tumor‐specific T‐cell repertoire that is prone to immunologic exhaustion and senescence, and (iii) highly mutable tumor targets capable of antigen loss and immune evasion. Future progress may come from innovations in the development of selective preparative regimens that eliminate or neutralize suppressive cellular populations, more effective immunologic adjuvants, and further refinement of agents capable of antagonizing immune check‐point blockade pathways.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1600-065x.2010.00979.x

Cites

210 of 210 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 8×
“These results contrast with the recent experience of combining the same gp100 peptide with bolus IL-2 where an increased fre- quency of objective responses and a significant improvement in progression free survival were observed compared with IL-2 administration alone (29).”
BackgroundInfluential
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645

Show all 210 references

Research works printed but not linked: 5

10.1172/JCI0216216 · DOI
Overwijk W, 2009, Peptide/incomplete freund adjuvant emulsion depots are a graveyard for tumor antigen‐specific CD8(+) T cells, J Immunother, 32, 971
Radvanyi L, 2008, Adoptive T‐cell therapy at the MD Anderson Cancer Center: early results and a promising future, J Immunother, 31, 924
Higano C, 2009, A Phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration‐resistant prostate cancer (CRPC), American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium (2009)
Small E, 2009, A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration‐resistant prostate cancer (CRPC), American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium (2009)

Sorted by citations

Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,559
Self-citation
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Self-citation
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,088
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
The Basis of Oncoimmunology
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 779
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 605
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami‐Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 507
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 372
Self-citation
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Kakarla, S., Chow, K. K. H., Mata, M., Shaffer, D. R., Song, X., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.110 · Cited by 355
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
van Montfoort, N., Borst, L., Korrer, M. J., Sluijter, M., Marijt, K. A., Santegoets, S. J. A. M., van Ham, V. J., Ehsan, I., Charoentong, P., André, P., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.028 · Cited by 339
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 337
Self-citation
Immune microenvironments in solid tumors: new targets for therapyPreprint
Shiao, S. L., Ganesan, A.-P., Rugo, H. S., & Coussens, L. M. (2011) · Genes & Development · doi:10.1101/gad.169029.111 · Cited by 331
Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P. J., Ji, Y., Hinrichs, C. S., Borman, Z. A., Kerkar, S. P., Scott, C. D., Finkelstein, S. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0503 · Cited by 288
Self-citation
Recent applications of immunomodulatory biomaterials for disease immunotherapy
Dai, H., Fan, Q., & Wang, C. (2022) · Exploration · doi:10.1002/exp.20210157 · Cited by 271
Metallic nanoparticles for cancer immunotherapy
Evans, E. R., Bugga, P., Asthana, V., & Drezek, R. A. (2017) · Materials Today · doi:10.1016/j.mattod.2017.11.022 · Cited by 248
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 249
Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy
Chew, V., Toh, H. C., & Abastado, J. (2012) · Journal of Oncology · doi:10.1155/2012/608406 · Cited by 224
Adoptive T-Cell Therapy for Cancer
Yang, J. C.-H., & Rosenberg, S. A. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 208
Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection
Aubert, R. D., Kamphorst, A. O., Sarkar, S., Vezys, V., Ha, S., Barber, D. L., Ye, L., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118450109 · Cited by 199
Extracellular Matrix‐Based Strategies for Immunomodulatory Biomaterials Engineering
Rowley, A. T., Nagalla, R. R., Wang, S., & Liu, W. F. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801578 · Cited by 193
Impact of the immune system and immunotherapy in colorectal cancer.
Markman, J. L., & Shiao, S. L. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.077 · Cited by 201
Targeting public neoantigens for cancer immunotherapy
Pearlman, A. H., Hwang, M. S., Konig, M. F., Hsiue, E. H.-C., Douglass, J., DiNapoli, S. R., Mog, B. J., Bettegowda, C., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00210-y · Cited by 194
The role of B7 family molecules in hematologic malignancy
Greaves, P., & Gribben, J. G. (2012) · Blood · doi:10.1182/blood-2012-10-385591 · Cited by 195
Updates on immunotherapy for colorectal cancer
Kalyan, A., Kircher, S. M., Shah, H. A., Mulcahy, M. F., & Benson, A. B. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.17 · Cited by 178
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy
Crane, C. A., Ahn, B. J., Han, S. J., & Parsa, A. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos014 · Cited by 176
Tumor cell lysates as immunogenic sources for cancer vaccine design
González, F. E., Gleisner, M. A., Falcón-Beas, F., Osorio, F., López, M. N., & Salazar‐Onfray, F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.982996 · Cited by 163
Retinoic acid controls the homeostasis of pre-cDC–derived splenic and intestinal dendritic cells
Klebanoff, C. A., Spencer, S. P., Torabi‐Parizi, P., Grainger, J. R., Roychoudhuri, R., Ji, Y., Sukumar, M., Muranski, P. J., Scott, C. D., Hall, J. A., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20122508 · Cited by 157
Self-citation
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
Eid, R. A., Samara, R. N., Ozbun, L. L., Abdalla, M. Y., Berzofsky, J. A., Friedman, K. M., Mkrtichyan, M., & Khleif, S. N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0095 · Cited by 164
Biomimetic Protein Nanoparticles Facilitate Enhanced Dendritic Cell Activation and Cross-Presentation
Molino, N. M., Anderson, A. K. L., Nelson, E. L., & Wang, S. (2013) · ACS Nano · doi:10.1021/nn403085w · Cited by 153
The split nature of tumor-infiltrating leukocytes
Lança, T., & Silva‐Santos, B. (2012) · OncoImmunology · doi:10.4161/onci.20068 · Cited by 154
Tumor Microenvironment and Myeloid-Derived Suppressor Cells
Umansky, V., & Sevko, A. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0126-7 · Cited by 147
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Raval, R. R., Sharabi, A. B., Walker, A. J., Drake, C. G., & Sharma, P. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-14 · Cited by 140
Combination of Radiotherapy and Immune Checkpoint Inhibitors
Pilones, K. A., Vanpouille‐Box, C., & Demaria, S. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.004 · Cited by 140
Natural and Synthetic Saponins as Vaccine Adjuvants
Wang, P. (2021) · Vaccines · doi:10.3390/vaccines9030222 · Cited by 133
The Abscopal Effect of Radiation Therapy
Craig, D. J., Nanavaty, N. S., Devanaboyina, M., Stanbery, L., Hamouda, D., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2021) · Future Oncology · doi:10.2217/fon-2020-0994 · Cited by 136
Melanoma-induced immunosuppression and its neutralization
Umansky, V., & Sevko, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.003 · Cited by 137
A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients
Vetsika, E., Koinis, F., Gioulbasani, M., Aggouraki, D., Koutoulaki, A., Skalidaki, E., Mavroudis, D., Georgoulias, V., & Kotsakis, A. P. (2014) · Journal of Immunology Research · doi:10.1155/2014/659294 · Cited by 127
Telomerase and the search for the end of cancer
D, S. M. M., Pooley, K. A., & Nitti, D. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.11.006 · Cited by 121
Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
Zanetti, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402669 · Cited by 133
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation
Papaspyridonos, M., Matei, I. R., Huang, Y., André, M. D. R., Brazier, H., Waite, J. C., Chan, A., Kalter, J., Ramos, I., Wu, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms7840 · Cited by 115
Immunotherapies for non-small-cell lung cancer and mesothelioma
Thomas, A., & Hassan, R. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70126-2 · Cited by 110
Cutaneous melanoma and the immunotherapy revolution (Review)
Leonardi, G. C., Candido, S., Falzone, L., Spandidos, D. A., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5088 · Cited by 107
Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy
Kondo, T., Morita, R., Okuzono, Y., Nakatsukasa, H., Sekiya, T., Chikuma, S., Shichita, T., Kanamori, M., Kubo, M., Koga, K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15338 · Cited by 106
Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy
Ramakrishnan, R., Huang, C., Cho, H.-I., Lloyd, M. C., Johnson, J., Ren, X., Altiok, S., Sullivan, D. M., Weber, J. S., Celis, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2236 · Cited by 108
Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer
Mondini, M., Nizard, M., Tran, T., Mauge, L., Loi, M., Clémenson, C., Dugué, D., Maroun, P., Louvet, E., Adam, J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1015 · Cited by 102
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon‐mediated rejection genes
Carretero, R., Wang, E., Rodríguez, A. I. E., Reinboth, J., Ascierto, M. L., Engle, A. M., Liu, H., Camacho, F. M., Marincola, F. M., Garrido, F., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26471 · Cited by 88
Clinically feasible approaches to potentiating cancer cell-based immunotherapies
Seledtsov, V. I., Гончаров, А. Г., & Seledtsova, G. V. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1009814 · Cited by 87
Regulation of mature T cell responses by the Wnt signaling pathway
Xue, H., & Zhao, D. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06302.x · Cited by 89
ImmTACs for targeted cancer therapy: Why, what, how, and which
Oates, J., Hassan, N. J., & Jakobsen, B. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.024 · Cited by 90
Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy
Zhang, Y., Fang, Z., Li, R., Huang, X., & Liu, Q. (2019) · Cancers · doi:10.3390/cancers11091314 · Cited by 85
Metastatic melanoma treatment: Combining old and new therapies
Davey, R. J., van der Westhuizen, A., & Bowden, N. A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.011 · Cited by 90
Immunotherapy for metastatic solid cancers
Turcotte, S., & Rosenberg, S. A. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.04.003 · Cited by 81
Functional differences between low- and high-affinity CD8+T cells in the tumor environment
Bos, R., Marquardt, K., Cheung, J., & Sherman, L. A. (2012) · OncoImmunology · doi:10.4161/onci.21285 · Cited by 79
Structural and dynamic control of T‐cell receptor specificity, cross‐reactivity, and binding mechanism
Baker, B. M., Scott, D. R., Blevins, S. J., & Hawse, W. F. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01165.x · Cited by 83
Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice
Gagliato, D. D. M., Cortés, J., Curigliano, G., Loi, S., Denkert, C., Pérez-García, J. M., & Holgado, E. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.003 · Cited by 80
Immunomodulatory and anticancer potential of Gan cao (Glycyrrhiza uralensis Fisch.) polysaccharides by CT-26 colon carcinoma cell growth inhibition and cytokine IL-7 upregulation in vitro
Ayeka, P. A., Bian, Y., Mwitari, P., Chu, X., Zhang, Y., Uzayisenga, R., & Otachi, E. O. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1171-4 · Cited by 79
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
Reustle, A., Marco, M. D., Meyerhoff, C., Nelde, A., Walz, J. S., Winter, S., Kandabarau, S., Büttner, F., Haag, M., Backert, L., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00731-8 · Cited by 78
Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles
Grandi, A., Tomasi, M., Zanella, I., Ganfini, L., Caproni, E., Fantappiè, L., Irene, C., Frattini, L. F., Isaac, S. J., König, E., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00253 · Cited by 77
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
Zandberg, D. P., Rollins, S., Goloubeva, O. G., Morales, R. E., Tan, M. T., Taylor, R., Wolf, J. S., Schumaker, L. M., Cullen, K. J., Zimrin, A. B., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1640-x · Cited by 77
Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor
McGray, A. R., Hallett, R. M., Bernard, D., Swift, S. L., Zhu, Z., Teoderascu, F., VanSeggelen, H., Hassell, J. A., Hurwitz, A. A., Wan, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.255 · Cited by 75
Telomerase as a Cancer Target. Development of New Molecules
Gómez, D. L. M., Armando, R. G., Cerrudo, C. S., Ghiringhelli, P. D., & Gomez, D. E. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160212122425 · Cited by 76
The emerging role of immunotherapy in colorectal cancer
Lynch, D. H., & Murphy, A. G. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.08.29 · Cited by 76
CD56dim CD16− Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α
Vujanovic, L. N., Chuckran, C. A., Lin, Y., Ding, F., Sander, C., Santos, P. M. L., Lohr, J., Mashadi-Hossein, A., Warren, S. E., White, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00014 · Cited by 79
Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response
Garu, A., Moku, G., Gulla, S. K., & Chaudhuri, A. (2015) · Molecular Therapy · doi:10.1038/mt.2015.215 · Cited by 74
Effective Cancer Vaccine Platform Based on Attenuated Salmonella and a Type III Secretion System
Xu, X. Y., Hegazy, W. A. H., Guo, L., Gao, X., Courtney, A. N., Kurbanov, S., Liu, D., Tian, G., Manuel, E. R., Diamond, D. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1169 · Cited by 72
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 72
Harnessing the Microbiome to Enhance Cancer Immunotherapy
Nelson, M. H., Diven, M. A., Huff, L. W., & Paulos, C. M. (2015) · Journal of Immunology Research · doi:10.1155/2015/368736 · Cited by 70
Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors
Zurac, S., Neagu, M. T., Constantin, C., Cioplea, M. D., Nedelcu, R., Bastian, A. E., Popp, C. G., Nichita, L., Andrei, R. T., Tebeică, T., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4391 · Cited by 69
Extracellular adenosine metabolism in immune cells in melanoma
Umansky, V., Shevchenko, I., Bazhin, A. V., & Utikal, J. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1553-8 · Cited by 69
Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes
Feichtinger, J., Aldeailej, I. M., Anderson, R., Almutairi, M. H., Almatrafi, A., Alsiwiehri, N. O., Griffiths, K., Stuart, N. S. A., Wakeman, J. A., Larcombe, L. D., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.580 · Cited by 65
Genetic cancer vaccines: current status and perspectives
Aurisicchio, L., & Ciliberto, G. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.689279 · Cited by 71
Immunotherapy in colorectal cancer: for the select few or all?
Arora, S. P., & Mahalingam, D. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.06.10 · Cited by 66
The role played by the microenvironment in site-specific metastasis
Klein-Goldberg, A., Maman, S., & Witz, I. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.029 · Cited by 64
Shared cancer neoantigens: Making private matters public
Klebanoff, C. A., & Wolchok, J. D. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20172188 · Cited by 62
Self-citation
Melanoma therapeutics: a literature review
Dhanyamraju, P. K., & Patel, T. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20210163 · Cited by 65
Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines
Ciocca, D. R., Cayado-Gutiérrez, N., Maccioni, M., & Cuello-Carrión, F. D. (2012) · Current Molecular Medicine · doi:10.2174/156652412803306684 · Cited by 59
Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy
Calmeiro, J., Carrascal, M. A., Gomes, C. M. F., Falcão, A. C., Cruz, M. T., & Neves, B. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0716-8 · Cited by 61
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level
Grenier, J. M., Yeung, S. T., & Khanna, K. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00610 · Cited by 58
Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging
Hartimath, S. V., Draghiciu, O., van de Wall, S., Manuelli, V., Dierckx, R., Nijman, H. W., Daemen, T., & de Vries, E. F. J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1248014 · Cited by 57
Improving T cell responses to modified peptides in tumor vaccines
Buhrman, J. D., & Slansky, J. E. (2012) · Immunologic Research · doi:10.1007/s12026-012-8348-9 · Cited by 54
Generation and application of human induced‐stem cell memory T cells for adoptive immunotherapy
Kondo, T., Imura, Y., Chikuma, S., Hibino, S., Omata‐Mise, S., Ando, M., Akanuma, T., Iizuka, M., Sakai, R., Morita, R., et al. (2018) · Cancer Science · doi:10.1111/cas.13648 · Cited by 51
Various ways to improve whole cancer cell vaccines
Cicchelero, L., de Rooster, H., & Sanders, N. N. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.911093 · Cited by 51
Therapeutic vaccines for colorectal cancer: The progress and future prospect
Shahnazari, M., Samadi, P., Pourjafar, M., & Jalali, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106944 · Cited by 53
Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma
Butterfield, L. H., Vujanovic, L. N., Santos, P. M. L., Maurer, D. M., Gambotto, A. A., Lohr, J., Li, C., Waldman, J., Chandran, U. R., Lin, Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0552-x · Cited by 50
Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis
Vo, J., Yang, L., Kurtz, S. L., Smith, S. G., Koppolu, B., Ravindranathan, S., & Zaharoff, D. A. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968001 · Cited by 49
Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses
Ghinnagow, R., Meester, J. D., Cruz, L. J., Aspord, C., Corgnac, S., Fernandez, É. M., Soulard, D., Fontaine, J., Chaperot, L., Charles, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1339855 · Cited by 49
The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes
Duechler, M., Pęczek, Ł., Żuk, K., Zaleśna, I., Jeziorski, A., & Czyż, M. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.09.003 · Cited by 47
Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy
Park, J., Thomas, S., & Münster, P. N. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 47
Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice
Najima, Y., Tomizawa-Murasawa, M., Saito, Y., Watanabe, T., Ono, R., Ochi, T., Suzuki, N., Fujiwara, H., Ohara, O., Shultz, L. D., et al. (2015) · Blood · doi:10.1182/blood-2014-10-604777 · Cited by 46
Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment
Baharom, F., Hermans, D., Delamarre, L., & Seder, R. A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01091-9 · Cited by 47
HLA-A*0201 Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients
Aspord, C., Leccia, M. ‐., Salameire, D., Laurin, D., Chaperot, L., Charles, J., & Plumas, J. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.152 · Cited by 46
CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice
Hansen, J. U., Lindenstrøm, T., Lindberg-Levin, J., Aagaard, C., Andersen, P. L., & Agger, E. M. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1156-6 · Cited by 45
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic
Breitbach, C. J., Parato, K. A., Burke, J., Hwang, T.-H., Bell, J. C., & Kirn, D. H. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.016 · Cited by 44
Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection
Jin, J., Zhu, P., Liao, Y., Li, J., Liao, W., & He, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4265 · Cited by 41
Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers
Cho, S., Dong, S., Parent, K. N., & Chen, M. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1077847 · Cited by 41
Immunotherapy for malignant glioma
Suryadevara, C. M., Sanchez-Perez, L. A., Sampson, J. H., Verla, T. G., Reap, E. A., Choi, B., & Fecci, P. E. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.151341 · Cited by 42

Authors: Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P.
Affiliations: National Institutes of Health (US)
Corresponding author: Restifo, Nicholas P.
ORCID: Klebanoff, Christopher A.
Yu, Zhiya
Restifo, Nicholas P.
Venue: Immunological Reviews
Publisher: Wiley
Published: 2010-12-28
Volume: 239
Issue: 1
Pages: 27-44
ISSN: 0105-2896 (ISSN-L)
1600-065X
DOI: 10.1111/j.1600-065x.2010.00979.x
PMC: PMC3075547
OpenAlex: W2132361489
Cited by: 271
References: 210
Citations by year: 2026: 2 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 19 · 2018: 14 · 2017: 16 · 2016: 21 · 2015: 36 · 2014: 22 · 2013: 33 · 2012: 34
FWCI: 2.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Immunological Reviews (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (ZIABC010763, ZIABC011037)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: therapeutic cancer vaccines, adoptive cell transfer, tumor microenvironment, regulatory T cells, myeloid cells, T cell exhaustion, tumor antigen loss, immune evasion, immunoadjuvant, immune checkpoint blockade, metastatic cancer, clinical trial efficacy
MeSH terms: Adjuvants, Immunologic, Antigens, Differentiation, T-Lymphocyte, Antigens, Neoplasm, Humans, Immunotherapy, Neoplasms, Randomized Controlled Trials as Topic, T-Lymphocyte Subsets, Treatment Outcome, Adoptive Transfer, Cancer Vaccines, Toll-Like Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic cancer vaccines: are we there yet?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks